Sexual dysfunction. Hypoactive sexual desire disorder
Conditions
Interventions
Intervention 1: Intervention group: Administration of Agnugol tablet containing 2.3-4.8 mg of vitex plant
manufactured by Gol Dara Co.
at 0, 4, 8,12 and 16 weeks. Intervention 2: Control group: Administration of placebo tablet containing starch 2.3-4.8 mg
manufactured by Shahid Beheshti Pharmaceutical Faculty
Tehran
at 0, 4, 8,12 and 16 weeks.
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 44 Years
Inclusion criteria
Inclusion criteria: Fertile women 15-44 years who referred for Pap smear Healthy in gynecological and physical examinations Seeking treatment for the improvement and enhancement of sexual function
Exclusion criteria
Exclusion criteria: single Pregnant and lactating Illiterate / cannot read and write Having a specific illness (thyroid problems, diabetes, psychiatric disorders, hyper-prolactonemia, liver problems, etc.) Stressful event in the last 6 months (death or disease of immediate family member, a major change in lifestyle) of any of the couples Mental problems (illness under the supervision or treatment of a physician) in each of the couples according to the woman's statement Treated for any sexual problems in each of the couples according to the woman's statement Alcohol or drug addiction in each of the couples according to the woman's statement Women whose husbands are unable to have normal sex (e.g., erectile dysfunction or premature ejaculation) Any illness in women, including abnormal bleeding, cervicitis and vaginitis without premenstrual tension and premenstrual syndrome. Taking vitamin supplements or hormonal pills like contraceptives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sexual function. Timepoint: Before the intervention, 4,812 and 16 weeks after the intervention. Method of measurement: Female Sexual Function Index questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sexual desire score. Timepoint: Before the intervention, 4, 8,12 and 16 weeks after the intervention. Method of measurement: Female Sexual Function Index questionnaire.;Sexual Arousal Score. Timepoint: Before the intervention, 4, 8,12 and 16 weeks after the intervention. Method of measurement: Female Sexual Function Index questionnaire.;Orgasm Score. Timepoint: Before the intervention, 4, 8,12 and 16 weeks after the intervention. Method of measurement: Female Sexual Function Index questionnaire.;Coitus of Pain Score. Timepoint: Before the intervention, 4, 8,12 and 16 weeks after the intervention. Method of measurement: Female Sexual Function Index questionnaire.;Sexual Satisfaction Score. Timepoint: Before the intervention, 4, 8,12 and 16 weeks after the intervention. Method of measurement: Female Sexual Function Index questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGiti ozgoli
Shahid Beheshti University of Medical Sciences
Outcome results
None listed